Hi, today we are going to talk about Amarin Corporation and its current landscape.
Amarin puts its Cardiovascular Drug named Vascepa to a key test today by the FDA committee. Back in 2012, the FDA initially approved Vascepa as the medication showed results in reduce triglyceride levels. Today the decision cames to determine if Amarin will be allowed to prescribe its medicament to reduce cardiovascular events. The approvement could be sharply bullish for the company considering that Cardiovascular diseases affect nearly half of Americans, as statics of the American Heart Associations.
Thank you for reading and leave your comments if you like.
To have access to our exclusive contents, join the Traders Heaven today! Link Below.
Disclaimer: All content of Golden Dragon has only educational and informational purposes, and never should be used or take it as financial advice.
Amarin puts its Cardiovascular Drug named Vascepa to a key test today by the FDA committee. Back in 2012, the FDA initially approved Vascepa as the medication showed results in reduce triglyceride levels. Today the decision cames to determine if Amarin will be allowed to prescribe its medicament to reduce cardiovascular events. The approvement could be sharply bullish for the company considering that Cardiovascular diseases affect nearly half of Americans, as statics of the American Heart Associations.
Thank you for reading and leave your comments if you like.
To have access to our exclusive contents, join the Traders Heaven today! Link Below.
Disclaimer: All content of Golden Dragon has only educational and informational purposes, and never should be used or take it as financial advice.
Conheça +: finfocus.com.br/links
免责声明
这些信息和出版物并非旨在提供，也不构成TradingView提供或认可的任何形式的财务、投资、交易或其他类型的建议或推荐。请阅读使用条款了解更多信息。
Conheça +: finfocus.com.br/links
免责声明
这些信息和出版物并非旨在提供，也不构成TradingView提供或认可的任何形式的财务、投资、交易或其他类型的建议或推荐。请阅读使用条款了解更多信息。